Αρχική World News FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma

On 24 July 2020, the US Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company), a CD19-directed genetically modified autologous T cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Approval was based on ZUMA-2 (NCT02601313), an open-label, multicentre, single-arm trial of 74 patients with relapsed or refractory MCL who had previously received anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody, and a Bruton tyrosine kinase inhibitor. Patients received a single infusion of brexucabtagene autoleucel following completion of lymphodepleting chemotherapy. The primary efficacy outcome measure was objective response rate (ORR) per Lugano (2014) criteria as assessed by an independent review committee.

Of the 60 patients evaluable for efficacy based on a minimum duration of follow-up for response of six months, the ORR was 87% (95% confidence interval [CI] 75, 94), with a complete remission (CR) rate of 62% (95% CI 48, 74). The estimated median duration of response was not reached (range of 0+ to 29.2+ months) after a median follow-up time for duration of response of 8.6 months. Of all 74 leukapheresed patients, the ORR as assessed by independent review committee (IRC) was 80% (95% CI 69, 88) with a CR rate of 55% (95% CI 43, 67).

The most common (≥10%) Grade 3 or higher reactions were anaemia, neutropenia, thrombocytopenia, hypotension, hypophosphatemia, encephalopathy, leukopenia, hypoxia, pyrexia, hyponatraemia, hypertension, infection – pathogen unspecified, pneumonia, hypocalcaemia, and lymphopenia.

FDA approved brexucabtagene autoleucel with a Risk Evaluation and Mitigation Strategy because of the risk of cytokine release syndrome and neurologic toxicities.

The recommended dose of brexucabtagene autoleucel is a single intravenous infusion of 2 x 106 CAR-positive viable T cells per kg body weight (maximum 2 x 108 CAR-positive viable T cells), preceded by fludarabine and cyclophosphamide lymphodepleting chemotherapy.

Full prescribing information for TECARTUS is available here.

This indication is approved under accelerated approval based on ORR and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

FDA granted orphan drug designation, breakthrough therapy designation, and priority review to brexucabtagene autoleucel for this indication.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Mothers Raise Girls Together After Discovering They Were Swapped At Birth

On New Years’ Even in 1998, two baby girls were born at a hospital in a Sicilian fishing port, Mazara del Vallo. The babies were...

Firefighters Band Together To Raise $30k For Breast Cancer Research & Care

Firefighters save lives as part of their job, but this group of firefighters are deemed heroes for more than just their firefighter duties. When they...

Foodie Friday: Butternut Squash Macaroni Casserole

As we move into fall, grocery stores and farmer’s markets are moving beautiful, health-filled butternut squash to their produce sections! When I saw this recipe...

Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment

September 24, 2021, by NCI Staff Most healthy human cells have 23 pairs of chromosomes, 1 through 22, plus X and Y. Many cancer cells,...

A winding journey into the world of children’s and young people’s cancer research

“It seems strange trying to describe my career path, as the words imply that there was some sort of intention or plan as to...

Early Signs of Efficacy of New Targeted Agents and Immunotherapies Reported for Multiple Cancers at ESMO Congress 2021 [ESMO Congress 2021 Press Release]

LUGANO, Switzerland – Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with...